Pharma BD Deal Intelligence
Valeant's $425M bolt-on of Sanofi's Dermik dermatology unit closed in December 2011, folding Sculptra, Benzaclin, and Carac into its acquisition-fueled roll-up. The aesthetics piece was partially cashed out via a 2014 sale to Galderma, but the remaining brands landed in Bausch Health's small dermatology segment, marked by repeated goodwill impairments as Valeant's broader strategy collapsed.
Valeant snaps up Sanofi's Dermik for $425M, adding Sculptra, BenzaClin and Carac and reinforcing its aggressive dermatology roll-up strategy under CEO Mike…
FTC required Valeant to divest topical 5-FU, BenzaClin/clindamycin-BPO generic rights, and a wrinkle treatment to Mylan and Spear Pharmaceuticals as a…
Valeant's twin acquisitions of Ortho and Dermik dramatically expand its prescription dermatology footprint, but FTC-mandated divestitures temper the strategic…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sanofi divested its US/Canada dermatology unit Dermik to Valeant for ~$425M cash. Portfolio included Sculptra, BenzaClin, Carac. Closed December 16, 2011 with FTC-mandated divestitures.
Assessment window: 5yr post-close.
40M US cases/yr · $2.9B US actinic keratosis treatment market 2023 (broader dermatology incl. aesthetics is multi-$B) · $206M Dermik 2010 sales (acquired portfolio)
Aesthetic and therapeutic dermatology spans cosmetic correction (wrinkles/folds via injectables like poly-L-lactic acid), inflammatory acne, and pre-cancerous sun-damaged skin (actinic keratosis). The category is driven by an aging population, sun-exposure history, and rising demand for office-administered cosmetic procedures, with primary care derms and aesthetic specialists as the prescribing channel.
Dermik's portfolio anchored Valeant in three commercially distinct subsegments. In aesthetic injectables, Sculptra (poly-L-lactic acid) competes with Allergan's Juvederm/Voluma hyaluronic acid fillers, Galderma's Restylane line, and Merz's Radiesse — Sculptra's longer-duration collagen-stimulation profile differentiates it in volume restoration. In topical acne, BenzaClin (clindamycin/benzoyl peroxide) faced generics plus combination products like GSK's Duac and Galderma's Epiduo. In actinic keratosis, Carac (5-fluorouracil 0.5%) competes with LEO Pharma's Picato (now withdrawn), Bausch's Efudex, and imiquimod (Aldara). The deal accelerated Valeant's transformation into a dermatology-led specialty pharma — by 2011 it had also acquired Ortho Dermatologics from J&J in parallel. The FTC required Valeant to divest topical 5-FU, BenzaClin/generic clindamycin-BPO and a tretinoin product to Mylan and Spear Pharmaceuticals to clear competitive overlap, shaping the final asset list. The transaction was foundational to Valeant's later identity as a roll-up acquirer of off-patent dermatology brands.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) (this deal) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. | 2014 | $475M | 23 |
← Browse all deals · How we score deals
More: 2011 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals